Dr. Tagawa on Targeting PSMA in Prostate Cancer

Video

In Partnership With:

Scott T. Tagawa, MD, MS, discusses the utility of beta and alpha emitters in targeting PSMA in prostate cancer.

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, and associate attending physician, Weill Cornell Medical Center/NewYork-Presbyterian Hospital, discusses the utility of beta and alpha emitters in targeting PSMA in prostate cancer.

Both patients and physicians are well aware of PSMA, says Tagawa. PSMA is found on the surface of prostate cancer cells and a couple of other areas of the body, such as the salivary glands, kidneys, and small intestines, explains Tagawa. However, PSMA is very selective and mostly found in prostate cancer; it can be targeted through imaging and treatment. Regarding treatment, 2 randomized studies have been completed but the field is awaiting those results, says Tagawa.

One of these studies utilized a small molecule with a beta emitter. Radiopharmaceuticals such as Lutetium-177-PSMA are a novel way to treat patients with advanced prostate cancer. This approach is has been shown to be effective, says Tagawa. Despite its promise, it is not able to kill all cells; it is not as powerful as an alpha emitter. An alpha emitter has higher energy and cell-killing ability, but that energy travels a much shorter distance, explains Tagawa. As such, use of these emitters requires getting next to the cell that will be killed because if it is in the wrong place, it could cause a lot more damage, concludes Tagawa.

Related Videos
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute